Mounjaro on the NHS: what your GP can actually prescribe right now

What NICE approved, and the strict criteria attached to it

NICE's appraisal of tirzepatide, published on 23 December 2024 and updated in September 2025, is unambiguous about who qualifies. The recommendation covers adults with a BMI of 35 or above who also have at least one weight-related comorbidity from a defined list: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the BMI threshold is 2.5 kg/m² lower throughout.

That threshold matters in practice. A BMI of 34.9 with high blood pressure does not qualify, however significant the health impact. The NICE guidance is explicit: if a patient hasn't lost at least 5% of their body weight after six months at the highest tolerated dose, continuing treatment should be reviewed. There is no open-ended prescription here.

The NHS eligibility rules for Mounjaro are phased further by cohort. The first cohort, live from June 2025, requires a BMI of 40 or above plus four or more of those five conditions. The second cohort (BMI 35–39.9 plus four or more conditions) was activated on 23 June 2026. A third phase, covering BMI 40 and above with three conditions, is expected around March 2027. Each phase opens access to a wider group, but the qualifying bar remains high at every stage.

Can your GP prescribe Mounjaro now, and will they?

Technically, yes, from 1 April 2026. NHS England's updated GP contract includes a provision for GP practices to prescribe tirzepatide as part of the phased rollout, subject to meeting the eligibility criteria above. In practice, the picture is patchier. GP participation is optional, not mandatory. Some practices have signed up; others haven't, citing workload, staffing, or local commissioning decisions. Whether your surgery offers this depends entirely on where you live and which Integrated Care Board covers your area.

Even in practices that do participate, patients must take part in wrap-around support, structured diet and activity guidance alongside the medicine. This is not a formality. NHS England's guidance makes clear it is a condition of prescribing, not an optional add-on. If a local service doesn't have that wrap-around infrastructure in place, the prescription may not follow even if you meet the BMI and comorbidity criteria.

There's also a timing factor worth knowing: NHS prescribing cycles, referral admin, and end-of-financial-year pressures can all affect how quickly a practice moves. If your GP is broadly supportive but says to come back in a few weeks, that's a real pattern. If you're hoping to start before a holiday or after a particular point in the month, the NHS timeline may not align. For anyone wondering whether a GP can prescribe Mounjaro and under what conditions, there's a dedicated guide covering exactly that. For a fuller breakdown of how to approach your GP about Mounjaro, there's more detail in that guide.

What the trial evidence shows about who benefits most

The case for accessing tirzepatide, by whatever route, rests on solid data. In SURMOUNT-1 (a randomised trial involving 2,539 adults with obesity and no diabetes) participants on the 15mg dose lost an average of around 20–21% of their body weight over 72 weeks, alongside a reduced-calorie diet and increased activity. The trial data, published in the New England Journal of Medicine, informed NICE's recommendation directly.

Head-to-head evidence is also available now. The SURMOUNT-5 trial, published in NEJM in 2025, compared tirzepatide with semaglutide 2.4mg (Wegovy) in adults with obesity and no diabetes over 72 weeks. Tirzepatide produced greater average weight reduction. NICE's appraisal committee noted this result, and indirect comparisons across the clinical programme consistently favour tirzepatide. These figures apply to people using the medicine alongside lifestyle changes, the treatment is an adjunct, not a replacement for them.

For anyone reading about their weight-loss treatment options more broadly, it's worth knowing that the trial populations included people who would qualify for private prescription too, not just those meeting NHS thresholds. Effectiveness in the evidence base is not conditional on how you access the medicine.

Private prescription if NHS access isn't there yet

For many people right now, NHS access to Mounjaro through a GP is either out of reach (the comorbidity and BMI criteria are genuinely strict) or delayed by the optional nature of GP participation and phased rollout timelines. Private prescription through a GPhC-registered online pharmacy is the alternative, no referral, no waiting list, subject to a prescriber deciding you're clinically suitable.

At nume, a real clinician reads every consultation; there is no automated decision-making. Every repeat order is reviewed again before it's approved. You can look up our pharmacy registration directly on the GPhC register (registration 9012878), which is the fastest way to confirm any online pharmacy is legitimate. The cost of private Mounjaro rose significantly after Eli Lilly's UK price change in September 2025, so it's worth understanding what a private treatment price includes before comparing providers. For a step-by-step picture of how buying Mounjaro privately works, that page covers the full process.

If you're in the group that does qualify for NHS Mounjaro through a GP, it's absolutely worth pursuing, and our guide on how to buy Mounjaro on the NHS walks through what that process currently looks like. If you're not, or the wait is too long, a private route through a regulated pharmacy provides the same licensed medicine with the same clinical review obligations. Speak to our prescribers to find out whether treatment is right for you.